Immunoendocrine alterations during human tuberculosis as an integrated view of disease pathology

NeuroImmunoModulation

Volumn 16, Issue 2, 2009, Pages 68-77

  Bottasso, Oscar ^a   Bay, María Luisa ^a   Besedovsky, Hugo ^b   Del Rey, Adriana ^b  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cell mediated immune response; Cytokines; Hormones; Tuberculosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 6; MYCOBACTERIUM ANTIGEN; PRASTERONE; PROLACTIN; THYROID HORMONE; TRANSFORMING GROWTH FACTOR BETA;

ADRENAL CELL; BACTERIUM CULTURE; CHRONIC DISEASE; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; DISEASE COURSE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; METABOLIC DISORDER; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; TUBERCULOSIS; WEIGHT REDUCTION;

ADRENAL CORTEX; ANIMALS; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DEHYDROEPIANDROSTERONE; HORMONES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MICE; NEUROIMMUNOMODULATION; PITUITARY-ADRENAL SYSTEM; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 60149106296     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000180261     Document Type: Review

References (102)

1. World Health Organization: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2006. www.who.int/entity/tb/publications/global- report/2006/pdf/full-report-correctedversion.pdf.
2. Flynn JL: Immunology of tuberculosis and implications in vaccine development. Tuberculosis 2004;84:93-101.
3. Small PM, Fujiwara PI: Management of tuberculosis in the United States. N Engl J Med 2001;345:189-200.
4. Stenger S, Modlin RL: T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol 1999;2:89-93.
5. Dannenberg AM Jr, Rook GA: Pathogenesis of pulmonary tuberculosis: an interplay between tissue-damaging and macrophage-activating immune responses: dual mechanisms that control bacillary multiplication; In Bloom BR (ed): Tuberculosis: Pathogenesis, Protection, and Control. Washington, ASM Press, 1994, pp 459-484.
6. Boom WH: The role of T-cell subsets in Mycobacterium tuberculosis infection. Infect Agents Dis 1996;5:73-81.
7. Cooper AM, Adams LB, Dalton DK, Appelberg R, Ehlers S: IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol 2002;10:221-226.
8. MacMicking JD, Taylor GA, McKinney JD: Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003;302:654-659.
9. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V: Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004;119:753-766.
10. Altare F, Jouanguy E, Lamhamedi S, Döffinger R, Fischer A, Casanova JL: Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 1998;10:413-417.
11. Bulat-Kardum L, Etokebe GE, Knezevic J, Balen S, Matakovic-Mileusnicy N, Zaputovic L, Pavelic J, Beg-Zecy Z, Dembic Z: Interferon-γ receptor-1 gene promoter polymorphisms (G-611A;T-56C) and susceptibility to tuberculosis. Scand J Immunol 2006;63:142-150.
12. Hernandez Pando R, Orozco H, Sampieri A, Pavon L, Velasquillo C, Larriva Sahd J, Alcocer JM, Madrid MV: Correlation between the kinetics of TH1/Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996;89:26-33.
13. Howard AD, Zwilling BS: Reactivation of tuberculosis is associated with a shift from type 1 to type 2 cytokines. Clin Exp Immunol 1999;115:428-434.
14. Sugawara I, Yamada H, Mizuno S, Iwakura Y: IL-4 is required for defense against mycobacterial infection. Microbiol Immunol 2000;44:971-979.
15. North RJ: Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 1998;113:55-58.
16. Erb KJ, Kirman J, Delahunt B, Chen W, Le Gros G: IL-4, IL-5 and IL-10 are not required for the control of M. bovis-BCG infection in mice. Immunol Cell Biol 1998;76:41-46.
17. Sanchez FO, Rodriguez JI, Garcia LF: Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls. Infect Immun 1994;62:5673-5678.
18. Schauf V, Rom WN, Smith KA, Sampaio EP, Meyn PA, Tramontana JM, Cohn ZA, Kaplan G: Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis 1993;168:1056-1059.
19. Surcel HM, Troye Blomberg M, Paulie S, Andersson G, Moreno C, Pasvol G, Ivanyi J: Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994;81:171-176.
20. van Crevel R, Karyadi E, Preyers F, Leenders M, Kullberg BJ, Nelwan RH, van der Meer JW: Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis 2000;181:1194-1197.
21. Lai CK, Ho S, Chan CH, Chan J, Choy D, Leung R, Lai KN: Cytokine gene expression profile of circulating CD4+ T cells in active pulmonary tuberculosis. Chest 1997;111:606-611.
22. Lin Y, Zhang M, Hofman FM, Gong J, Barnes PF: Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 1996;64:1351-1356.
23. Dlugovitzky D, Torres-Morales A, Rateni L, Farroni MA, Largacha C, Molteni O, Bottasso OA: Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degree of pulmonary involvement. FEMS Immunol Microbiol 1997;18:203-207.
24. del Rey A, Mahuad CV, Bozza V, Bogue C, Farroni MA, Bay ML, Bottasso OA, Besedovsky HO: Endocrine and cytokine responses in humans with pulmonary tuberculosis. Brain Behav Immun 2007;21:171-179.
25. Dlugovitzky D, Bay ML, Rateni L, Urízar L, Rondelli FM, Largacha C, Farroni MA, Molteni O, Bottasso OA: In vitro synthesis of interferon-γ, interleukin-4, transforming growth factor-β, and interleukin 1-β by peripheral blood mononuclear cells from tuberculosis patients. Relationship with the severity of pulmonary involvement. Scand J Immunol 1999;49:210-217.
26. Valone SE, Rich EA, Wallis SR, Ellner JJ: Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun 1998;56:3313-3315.
27. Henderson RA, Watkins SC, Flynn JL: Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 1997;159:635-643.
28. Orme IM, Cooper AM: Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 1999;20:307-312.
29. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-740.
30. Senaldi G, Yin S, Shaklee CL, Piguet PF, Mak TW, Ulich TR: Corynebacterium parvum-and Mycobacterium bovis bacillus Calmette-Guérin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996;157:5022-5026.
31. Gomez-Reino JJ, Carmona L, Angel Descalzo M: Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-761.
32. Law K, Weiden M, Harkin T, Tchou-Wong K, Chi C, Rom WN: Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by broncoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 1996;153:799-804.
33. Dlugovitzky D, Bay ML, Rateni L, Fiorenza G, Vietti L, Farroni MA, Bottasso OA: Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells from patients with pulmonary tuberculosis. Clin Exp Immunol 2000;122:343-349.
34. 2 by peripheral blood mononuclear cells from tuberculosis patients. Clin Exp Immunol 1990;81:319-324.
35. Dlugovitzky D, Bottasso O, Dominino JC, Valentini E, Hartopp R, Singh M, Stanford C, Stanford J: Clinical and serological studies of tuberculosis patients receiving immunotherapy with Mycobacterium vaccae. Respir Med 1999;93:557-562.
36. Roach TI, Barton CH, Chatterjee D, Blackwell JM: Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-alpha. J Immunol 1993;150:1886-1896.
37. Romagnani S: Lymphokine production by human T-cells in disease states. Ann Rev Immunol 1994;12:227-257.
38. Wilkinson RJ, Patel P, Llewelyn M, Hirsch CS, Pasvol G, Snounou G, Davidson R, Toossi Z: Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1β on tuberculosis. J Exp Med 1999;189:1863-1874.
39. VanHeyningen TK, Collins HL, Russell DG: IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses. J Immunol 1997;158:330-337.
40. Hoheisel G, Izbicki G, Roth M, Chan CH, Leung JC, Reichenberger F, Schauer J, Perruchoud AP: Compartmentalization of pro-inflammatory cytokines in tuberculous pleurisy. Respir Med 1998;92:14-17.
41. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40-47.
42. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH: Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997;65:4843-4849.
43. Saunders BM, Frank AA, Orme IM, Cooper AM: Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis in fection. Infect Immun 2000;68:3322-3326.
44. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
45. Shaw TC, Thomas LH, Friedland JS: Regulation of IL-10 secretion after phagocytosis of Mycobacterium tuberculosis by human monocytic cells. Cytokine 2000;12:483-486.
46. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, Berezovskaya A, Rousset D, Reynes JM, Goldfeld AE: IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317-1325.
47. Barnes PF, Abrams JS, Lu S, Sieling PA, Rea TH, Modlin RL: Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Infect Immun 1993;61:197-203.
48. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, Wallis RS, Edmonds K, Okwera A, Mugerwa R, Peters P, Ellner JJ: Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 1999;180:2069-2073.
49. Torres M, Herrera T, Villareal H, Rich EA, Sada E: Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect Immun 1998;66:176-180.
50. Bottasso O, Bay ML, Besedovsky H, del Rey A: The immuno-endocrine component in the pathogenesis of tuberculosis. Scand J Immunol 2007;66:166-175.
51. Othieno C, Hirsch CS, Hamilton BD, Wilkinson K, Ellner JJ, Toossi Z: Interaction of Mycobacterium tuberculosis-induced transforming growth factor β1 and interleukin-10. Infect Immun 1999;67:5730-5735.
52. Toossi Z, Ellner JJ: The role of TGF beta in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol 1998;87:107-114.
53. Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-beta: biological function and chemical structure. Science 1986;233:532-534.
54. Sodhi A, Gong JH, Silva C, Qian D, Barnes PF: Clinical correlates of interferon γ production in patients with tuberculosis. Clin Infect Dis 1997;25:617-620.
55. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, de Waal-Malefyt R, Ottenhoff TH: Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004;101:4560-4565.
56. Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, Ghilardi N, de-Sauvage F, Cooper AM: IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005;175:788-795.
57. Marie JC, Letterio JJ, Gavin M, Rudensky AY: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005;201:1061-1067.
58. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L: TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-1208.
59. Bommireddy R, Doetschman T: TGF-beta, T-cell tolerance and anti-CD3 therapy. Trends Mol Med 2004;10:3-9.
60. Belkaid Y: Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007;7:875-888.
61. Ribeiro-Rodrigues R, Resende CT, Rojas R, Toossi Z, Dietze R, Boom WH, Maciel E, Hirsch CS: A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 2006;144:25-34.
62. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A: Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006;173:803-810.
63. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231-234.
64. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
65. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al: IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-377.
66. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-957.
67. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F: Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-949.
68. Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, Black G, Hassan HY, Wilkinson RJ, Walzl G, Gelderbloem SJ, Mahomed H, Hussey GD, Hanekom WA: Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008;180:1962-1970.
69. Besedovsky HO, del Rey A: Immune-neuroendocrine interactions: facts and hypothesis. Endocr Rev 1996;17:64-95.
70. Turnbull AV, Rivier CL: Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999;79:1-71.
71. Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999;10:359-368.
72. Miyaura H, Iwata M: Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J Immunol 2002;168:1087-1094.
73. Ramirez F, Fowell DJ, Puklavec M, Simmonds S, Mason D: Glucocorticoids promote a Th2 cytokine response by CD4+ T cells in vitro. J Immunol 1996;156:2406-2412.
74. Padgett DA, Sheridan JF, Loria R: Steroid hormone regulation of a polyclonal Th2 immune response. Ann NY Acad Sci 1995;774:323-325.
75. Dillon JS: Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005;4:377-385.
76. Mahuad C, Bay ML, Farroni MA, Bozza V, Del Rey A, Besedovsky H, Bottasso OA: Cortisol and dehydroepiandrosterone affect the response of peripheral blood mononuclear cells to mycobacterial antigens during tuberculosis. Scand J Immunol 2004;60:639-646.
77. Wilckens T, de Rijk R: Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997;19:418-424.
78. Kelestimur F, Goktas Z, Gulmez I, Unluhizarci K, Bayram F, Ozesmi M, Guven M, Tutus A: Low dose (1 microgram) adrenocorticotropin stimulation test in the evaluation of hypothalamo-pituitary-adrenal axis in patients with active pulmonary tuberculosis. J Endocrinol Invest 2000;23:235-239.
79. Rook GAW, Honour J, Kon OM, Wilkinson RJ, Davidson R, Shaw RJ: Urinary steroid metabolites in tuberculosis: a new clue to pathogenesis. Q J Med 1996;89:333-341.
80. Verbon A, Juffermans N, Van Deventer S, Speelman P, Van Deutekom H, Van Der Poll T: Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 1999;115:110-113.
81. Van den Berghe G: Endocrine evaluation of patients with critical illness. Endocrinol Metab Clin North Am 2003;32:385-410.
82. Straub RH, Pongratz G, Schölmerich J, Kees F, Schaible TF, Antoni C, Kalden JR, Lorenz HM: Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. Arthritis Rheum 2003;48:1504-1512.
83. Haidan A, Hilbers U, Bornstein SR, Ehrhart-Bornstein M: Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP). Peptides 1998;19:1511-1517.
84. Lebrethon MC, Jaillard C, Naville D, Begeot M, Saez JM: Effects of transforming growth factor-beta 1 on human adrenocortical fasciculata- reticularis cell differentiated functions. J Clin Endocrinol Metab 1994;79:1033-1039.
85. Keven K, Uysal AR, Erdogan G: Adrenal function during tuberculous infection and effects of antituberculosis treatment on endogenous and exogenous steroids. Int J Tuberc Lung Dis 1998;2:419-424.
86. Ellis E, Tayoub F: Adrenal function in tuberculosis. Br J Dis Chest 1986;80:7-12.
87. Bozza VV, D'Attilio L, Mahuad CV, Giri AA, del Rey A, Besedovsky H, Bottasso O, Bay ML: Altered cortisol/DHEA ratio in tuberculosis patients and its relationship with abnormalities in the mycobacterial-driven cytokine production by peripheral blood mononuclear cells. Scand J Immunol 2007;66:97-103.
88. Imrich R: The role of neuroendocrine system in the pathogenesis of rheumatic diseases. Endocr Regul 2002;36:95-106.
89. Foster MP, Jensen ER, Montecino-Rodriguez E, Leathers H, Horseman N, Dorshkind K: Humoral and cell-mediated immunity in mice with genetic deficiencies of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormone. Clin Immunol 2000;96:140-149.
90. Malkin J, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH: The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J. Clin Endocrinol Metab 2004;89:3313-3318.
91. Cutolo M, Capellino S, Montagna P, Villaggio B, Sulli A, Seriolo B, Straub RH: New roles for estrogens in rheumatoid arthritis. Clin Exp Rheumatol 2003;21:687-690.
92. Dorshkind K, Horseman ND: The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000;21:292-312.
93. Plata-Salaman CR: Cytokines and feeding. Int J Obes 2001;25:S48-S52.
94. Langhans W: Anorexia of infection: current prospects. Nutrition 2000;16:996-1005.
95. Schwenk A, Macallan DC: Tuberculosis, malnutrition and wasting. Curr Opin Clin Nutr Metab Care 2000;3:285-291.
96. Mahuad C, Bozza V, Pezzotto SM, Bay ML, Besedovsky H, del Rey A, Bottasso O: Impaired immune responses in tuberculosis patients are related to weight loss that coexists with an immunoendocrine imbalance. Neuroimmunomodulation 2007;14:193-199.
97. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-79.
98. Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO: Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 2003;88:4379-4383.
99. van Lettow M, van der Meer JW, West CE, van Crevel R, Semba RD: Interleukin-6 and human immunodeficiency virus load, but not plasma leptin concentration, predict anorexia and wasting in adults with pulmonary tuberculosis in Malawi. J Clin Endocrinol Metab 2005;90:4771-4776.
100. Dallman M, Strack A, Akana S, Bradbury M, Hanson E, Scribner K, Smith M: Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol 1993;14:303-347.
101. Kellendonk C, Eiden S, Kretz O, Schutz G, Schmidt I, Tronche F, Simon E: Inactivation of the GR in the nervous system affects energy accumulation. Endocrinology 2002;143:2333-2340.
102. Moret Y, Schmid-Hempel P: Survival for immunity: the price of immune system activation for bumblebee workers. Science 2000;290:1166-1168.